Staidson (Beijing) Biopharmaceuticals Co., Ltd Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Beijing China (2002)

Organization Overview

First Clinical Trial
2019
NCT05360927
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Staidson (Beijing) Biopharmaceuticals Co., Ltd

Active Ingredients

Drugs in Phase 3 Trials (1)

bdb-001 (7 trials)

Drugs in Phase 2 Trials (4)

cyclophosphamide (cytoxan) (1 trial)

stsa-1002 (6 trials)

stsg-0002 (2 trials)

stsp-0601 (3 trials)

Drugs in Phase 1 Trials (3)

stsa-1005 (1 trial)

stsa-1201 (1 trial)

stsa-1301 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pneumonia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 20
  • # of Trial APIs: 8